fulvestrant
information and resources from the National Cancer Institute
fulvestrant
A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. fulvestrant
A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines.
Faslodex
the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy
IPR Apr 25 2002
|
|
|
|
news articles
A 62-Year-Old Woman With a New Diagnosis of Breast Cancer Mar 21, 2006
Journal of American Medical Association (subscription), Combinations of endocrine agents (eg, aromatase inhibitors plus the pure estrogen antagonist fulvestrant) are of interest, 53 as is the simultaneous use of ...
Phase II Trial Explores Faslodex® After Aromatase Inhibitor Mar 6, 2006
Cancer Consultants (press release), ...advanced breast cancer that progresses after therapy with an aromatase inhibitor, treatment with the antiestrogen drug Faslodex® (fulvestrant) resulted in ...
(PRN) Analysis Demonstrates Time to Response With FASLODEX(R) ... Dec 10, 2005
Houston Chronicle, 10 /PRNewswire-FirstCall/ -- An analysis of two Phase III studies evaluating time to response (TTR) with FASLODEX(R) (fulvestrant) Injection compared to ...
No Differences in Time to Response for Fulvestrant and Anastrozole ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- Doctors said that treatment with daily oral anastrozole or a once-monthly injection with fulvestrant showed no ...
Estrogen May Induce Apoptosis In Breast Cancer Resistant to ... Dec 7, 2005
Cancerpage.com, 7 cells in vitro, with maximum stimulation at 0.1 nanomolar concentration, whereas treatment with the estrogen receptor antagonist fulvestrant reduced their ...
Low-Dose Estrogen May Fight Breast Cancer Dec 7, 2005
Forbes Kill rates were higher in cells treated with estradiol, compared to those treated with fulvestrant, an estrogen-blocker, or cells from an untreated control ...
Researchers uncover mechanisms of estrogen in promoting cell death ... Dec 6, 2005
EurekAlert (press release), ...positive breast cancers), and apoptosis of such cells can be induced with treatments that block estrogen, such as tamoxifen, fulvestrant, or aromatase ...
Faslodex® Provides Clinical Benefit for Women with Breast Cancer ... Dec 1, 2005
Cancer Consultants (press release), According to a recent article published by the European Journal of Cancer, the anti-estrogen Faslodex® (fulvestrant) provides clinical benefit to women with ...
Researchers Say Estrogen Can Kill Breast Cancer Cells Once Fueled ... Dec 7, 2005
Science Daily (press release) Women with these types of breast cancers are treated with drugs that that block estrogen, such as tamoxifen, fulvestrant, or aromatase inhibitors, causing the ...
New Data Show Survival Benefit for Arimidex(TM) in Early Breast ... Dec 9, 2005
news aktuell (Pressemitteilung), ...development of its current anti-cancer therapies including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen ...
Gamma-linolenic acid inhibits action of Her-2/neu, responsible for ... Nov 20, 2005
Xagena.it, Lupu and Menendez recently demonstrated that GLA also enhances the efficacy of anti-estrogens, such as Tamoxifen and Fulvestrant ( Faslodex ). ...
AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
PR Newswire (press release), CASODEX(R) (bicalutamide), CRESTOR(R) (rosuvastatin calcium), EMLA Cream (lidocaine 2.5% and prilocaine 2.5%), FASLODEX(R) (fulvestrant), NEXIUM(R ...
|
|
